STAT+: Novo Nordisk’s obesity drug Wegovy cleared to trea…
The latest developments in health are reshaping the market landscape. Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH….
This story is developing and could have significant implications for investors and market participants. Stay tuned for updates as this situation unfolds.
Bottom line: Keep watching this space – it could impact your portfolio.
Source: STAT
